CNTA vs MRK vs KO vs PFE vs AZN

For growth investors, AstraZeneca PLC (AZN) is the stronger pick with 8.

6% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Merck & Co. , Inc. (MRK) offers the better valuation at 16. 6x trailing P/E (23. 2x forward), making it the more compelling value choice. Analysts rate Centessa Pharmaceuticals plc (CNTA) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 16. 6x versus AstraZeneca PLC at 27. 9x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: AstraZeneca PLC wins at 0. 81x versus The Coca-Cola Company's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Centessa Pharmaceuticals plc (CNTA) delivered a total return of +83.

2%, compared to -14. 2% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: AZN returned +276. 4% versus PFE's +25. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Centessa Pharmaceuticals plc's 1. 24β — meaning CNTA is approximately -718% more volatile than KO relative to the S&P 500. On balance sheet safety, Centessa Pharmaceuticals plc (CNTA) carries a lower debt/equity ratio of 1% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AstraZeneca PLC (AZN) is pulling ahead at 8.

6% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190. 7% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, AZN leads at 9. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus -1316. 9% for Centessa Pharmaceuticals plc — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -1384. 6% for CNTA. At the gross margin level — before operating expenses — CNTA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, AstraZeneca PLC (AZN) is the more undervalued stock at a PEG of 0. 81x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 8x forward P/E versus 25. 2x for The Coca-Cola Company — 16. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AZN: 18. 5% to $216. 00.

In this comparison, PFE (6.

6% yield), MRK (2. 7% yield), KO (2. 5% yield), AZN (1. 8% yield) pay a dividend. CNTA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Both have compounded well over 10 years (KO: +121. 1%, CNTA: +82. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CNTA (Healthcare) and MRK (Healthcare) and KO (Consumer Defensive) and PFE (Healthcare) and AZN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CNTA is a small-cap quality compounder stock; MRK is a large-cap deep-value stock; KO is a large-cap quality compounder stock; PFE is a mid-cap income-oriented stock; AZN is a large-cap quality compounder stock. MRK, KO, PFE, AZN pay a dividend while CNTA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.